Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are an adult aged 18 or older
- You have been diagnosed with one of the following cancers: breast, ovarian, lung, stomach, colorectal, esophageal, uterine, head and neck, or sarcoma
- You have a plan in place to receive chemotherapy or radiation treatment for your cancer
- You have never previously received chemotherapy or radiation treatment for your current cancer diagnosis
Who may not be able to join:
- You do not have a planned treatment involving chemotherapy, radiation, or a type of targeted drug called a PARP inhibitor
- You have already received chemotherapy or radiation as treatment for your current cancer
- You have a history of any blood cancer, such as leukemia, lymphoma, myelodysplastic syndrome, or multiple myeloma (including a slow-growing form called smoldering multiple myeloma) — however, people with certain early or borderline blood-related conditions (such as CHIP, CCUS, MBL, or MGUS) may still be eligible, so please confirm with the trial site if any of these apply to you
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lachelle D Weeks, MD, PhD, Dana-Farber Cancer Institute
Phone: 857-215-1943
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Prevalence of clonal hematopoiesis; Gene distribution of clonal hematopoiesis; Change in clonal hematopoiesis variant allele fraction; Solid malignancy progression; Overall survival; Development of hematologic toxicity; Development of therapy-related myeloid neoplasm (t-MN)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.